EchoGen
Withdrawn
This medicine's authorisation has been withdrawn
dodecafluoropentane
MedicineHumanWithdrawn
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for EchoGen has been withdrawn at the request of the marketing authorisation holder.
Product information
22/01/2001
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- EchoGen
- Active substance
- dodecafluoropentane
- International non-proprietary name (INN) or common name
- dodecafluoropentane
- Therapeutic area (MeSH)
- Echocardiography
- Anatomical therapeutic chemical (ATC) code
- V08DA
Pharmacotherapeutic group
Contrast mediaTherapeutic indication
EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation.
EchoGen should only be used in patients where the study without contrast enhancement is inconclusive.
This page was last updated on